Interim analysis of Pivekimab sunirine for patients with BPDCN – Naveen Pemmaraju
I recently had the honor of delivering an oral presentation on our international group’s clinical trial – interim analysis of Pivekimab sunirine (IMGN632, PVEK, CD123) for patients with BPDCN at the European Hematology Association annual meeting EHA23 in Frankfurt, Germany 🇩🇪 June 8-11,2023.
Fantastic experience overall, delighted to continue my life’s work to keep bringing awareness and keep leading research innovations & developments on behalf of our patients in the field of rare disease Rare Blood Cancers and BPDCN 🙏🏾 to all of our co-investigators, patients, families, supporters & colleagues around the world 🌍!
Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center, including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department. Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.
